SIRS – Treatment of diseases related to vascular leakage
Vascular leakage is a common and detrimental factor in many clinically critial situations. SIRS develops strategies based on FX06 to counter the effects and improve clinical outcomes.
A development stage biopharmaceutical company that develops FX06, a fibrin-derived peptide for the treatment of diseases related to vascular leakage e.g., ARDS in patients with underlying COVID-19 infection.
Industry
Therapeutics
